The Effects of Adding Dexamethasone in the Quadratus Lumborum Block

NCT ID: NCT04496193

Last Updated: 2020-08-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The quadratus lumborum block is widely used in abdominal surgery for post-operative analgesia. It is now also used for pain relief after hip surgery. Under the traditional blocking method, a high concentration of long-acting local anesthetic is used in order to achieve a long-term blocking effect. However, this is also likely to cause the patient's quadriceps weakness during the block period, increasing the risk of the patient falling during rehabilitation. It also increases systemic local anesthetic poisoning and may even trigger the risk of serious side effects such as cardiac arrest. Ropivacaine is a novel long-acting topical amine anesthetics that lasts long and has anesthetic and analgesic effects. Its pharmacological characteristics are low cardiotoxicity, sensory block and motor block separation at low concentrations more obvious, and with the external peripheral vasoconstriction. Therefore, the drug is especially suitable for postoperative analgesia.

Dexamethasone is a synthetic corticosteroid for the treatment of a wide range of symptoms including rheumatic diseases, certain skin diseases, severe allergies, asthma, chronic obstructive pulmonary disease, cerebral edema, and may also be combined with antibiotics for tuberculosis patients. It is becoming more common to use steroids as an adjuvant to local anesthetics in peripheral nerve block. Steroids have neurological blockade effects by blocking the nociceptive transmission of pith-type C-fibers and inhibiting the release of ectopic neurons. Dexamethasone, as a local anesthetic adjuvant in peripheral nerve block, has also been widely studied recently.

In order to reduce the incidence of long-acting topical anesthetics from the nerve block in the quadratus lumborum block, reducing the local anesthetic concentration is a feasible method. However, this will also result in a shorter time to neurological block. The investigators hypothesized that the addition of Dexamethasone 5 mg to low concentrations (0.25%) of Ropivacaine would prolong postoperative analgesia. Therefore, the purpose of this study was to compare the postoperative analgesia and the side effects of postoperative quadratus lumborum block with the addition of Dexamethasone 4mg to Ropivacaine (0.25%) in low concentrations and Ropivacaine (0.5%) alone.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Test drug:

1. Name: Dexamethasone sod. Phosphate
2. Dosage form: 5 milligram (mg)/1 milliliter (mL)/Amp
3. Dose(s): 4mg
4. Dosing schedule: Dexamethasone 4mg adds into 0.25% Ropivacaine 20 mL
5. Mechanism of action: Synthesis of adrenocortical hormones, has a strong anti-inflammatory effect, can prolong the effect of local anesthetic drugs
6. Pharmacological category: HS051 Glucocorticoids

Study design:

1\. ☑ Control: ☑ placebo(N/S 0.8 mL + 0.25% Ropivacaine 20 mL)

* active (Dexamethasone 4mg+0.25% Ropivacaine 20 mL)
* others(N/S 0.8 mL + 0. 5% Ropivacaine 20 mL) □ Uncontrolled 2. Blinding: □ open-label □ single blind ☑ double blind □ others 3. Randomized: ☑ yes □ no 4. ☑ Parallel □ cross-over □ others 5. Duration of study:from Institutional Review Board (IRB) approval \~to 12, 31, 2022 ,total 24 months Duration of Enrollment : from IRB approval \~to 12, 31, 2022 ,total 24 months Duration of treatment:from IRB approval \~to 12, 31, 2022 ,total 24 months Duration of follow-up: from IRB approval \~to 12, 31, 2022 ,total 24 months

* Multi-national □multi-center(Taiwan) ☑single center(Taiwan) 6. Number of subjects: 90 7. Is there any of the followings included Data Safety and Monitoring Board (DSMB)
* yes ☑ no

Assessment criteria:

1\. Efficacy:

1. The intensity of pain was assessed using a 0 to 10 Numerical Rating Scale (NRS) to quantify their degree of pain; where 0 means no pain and 10 the worst pain imaginable.
2. The analgesic activity was assessed using standard measures during the 48-hour treatment period: baseline pain intensity, time to rescue medication, and overall patient evaluation of study medication.

2\. Safety:

1. Record the hemodynamic parameters during the 60-minute observation period in the anesthesia recovery room.
2. The severity of postoperative side effects (nausea, vomiting, pruritus) was quantified using different scales. Other side effects, including dizziness and drowsiness, are also recorded.
3. Motor block is assessed using Modified Bromage Scale.

3\. Pharmacokinetics: None

4\. Quality of life:

1. analgesic activity and duration of action
2. patient satisfaction

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Analgesia Motor Activity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group lower dose ropivacaine with dexamethasone

Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + dexamethasone 0.8 ml (4mg) at the end of surgery

Group Type EXPERIMENTAL

Quadratus Lumborum block

Intervention Type PROCEDURE

Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.

Group higher dose ropivacaine with N/S

Quadratus lumborum block was administered with 0.5% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery

Group Type ACTIVE_COMPARATOR

Quadratus Lumborum block

Intervention Type PROCEDURE

Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.

Group lower dose ropivacaine with N/S

Quadratus lumborum block was administered with 0.25% Ropivacaine 20 ml + N/S 0.8 ml at the end of surgery

Group Type PLACEBO_COMPARATOR

Quadratus Lumborum block

Intervention Type PROCEDURE

Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quadratus Lumborum block

Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anesthesiologists (ASA) classification: I \~ III
* Patients who received quadratus lumborum block for post-hip surgery analgesia

Exclusion Criteria

* Lumbar plexus degeneration,
* Coagulation abnormalities with international normalized ratio (INR) \> 1.5
* Obvious heart, lung, liver or kidney disease
* Body mass index less than 18.5 or greater than 35
* Pregnancy
* Regular use of steroids or opiates Opioids
* Chronic medication or alcohol abuse
* Previous allergies or adverse reactions to opiates, dexamethasone, or ropivacaine
Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hung-Te Hsu, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Anesthesiology, Kaohsiung Medical University Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hung-Te Hsu, MD, PhD

Role: CONTACT

+88673121101 ext. 7033

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KMUHIRB-F(I)-20200099

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.